HRP20130109T4 - Formulacije kaspofungina - Google Patents
Formulacije kaspofungina Download PDFInfo
- Publication number
- HRP20130109T4 HRP20130109T4 HRP20130109TT HRP20130109T HRP20130109T4 HR P20130109 T4 HRP20130109 T4 HR P20130109T4 HR P20130109T T HRP20130109T T HR P20130109TT HR P20130109 T HRP20130109 T HR P20130109T HR P20130109 T4 HRP20130109 T4 HR P20130109T4
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- caspofungin
- composition according
- solution
- formulation
- Prior art date
Links
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 title claims 12
- 229960003034 caspofungin Drugs 0.000 title claims 12
- 239000000203 mixture Substances 0.000 title claims 12
- 108010020326 Caspofungin Proteins 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000243 solution Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 5
- 239000000945 filler Substances 0.000 claims 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 239000004067 bulking agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000008176 lyophilized powder Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012906 subvisible particle Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 241000228257 Aspergillus sp. Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 239000008156 Ringer's lactate solution Substances 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 239000011236 particulate material Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 238000002407 reforming Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (13)
1. Farmaceutski sastav, naznačen time, da obuhvaća
a) kaspofungin diacetat ili kaspofungin dipropionat, i
b) farmaceutski prihvatljivu količinu punila za povećanje mase, učinkovitog za tvorbu liofiliziranog kolača;
pri čemu se ne dodaje nikakva dodatna količina sredstva za promjenu pH vrijednosti prilikom tvorbe sastava.
2. Farmaceutski sastav prema zahtjevu 1, naznačen time, da obuhvaća diacetat kaspofungina.
3. Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da se punilo za povećanje mase sastoji od jednog ili više sredstava za povećanje mase, te da je spomenuto punilo za povećanje mase poželjno manitol, saharoza ili njihova kombinacija.
4. Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da obuhvaća
a) 0,1 mg/ml do 500 mg/ml, poželjno 20 mg/ml do 60 mg/ml kaspofungina, računajući to kao kaspofungin bazu,
b) 10 mg/ml do 200 mg/ml, poželjno 40 mg/ml do 60 mg/ml pomoćnog sredstva koje je punilo za povećanje mase, poželjno mješavina šećernih punila za povećanje mase, što je učinkovito za tvorbu liofiliziranog kolača,
i vodu.
5. Farmaceutski sastav prema zahtjevu 4, naznačen time, da obuhvaća
a) 42 mg/ml kaspofungina, računajući to kao kaspofungin bazu, što odgovara za 46,6 mg/ml kaspofungin diacetata,
b) 50 mg/ml punila za povećanje mase, koje je mješavina 20 mg/ml manitola i 30 mg/ml saharoze,
i vodu.
6. Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da ima pH vrijednost od 5 do 7, poželjno od 5,5 do 6,5, najbolje 6,0.
7. Liofilizirani prašak, naznačen time, da se dobiva liofilizacijom farmaceutskog sastava prema bilo kojem od prethodnih zahtjeva, te time, da je pogodan za preoblikovanje u svrhu tvorbe tekućeg sastava za parenteralnu, poželjno intravenoznu primjenu.
8. Farmaceutski sastav, naznačen time, da se dobiva preoblikovanjem liofiliziranog praška prema zahtjevu 7 s vodenom otopinom odabranom između destilirane i/ili sterilne vode za injekcije; bakteriostatičke vode za injekcije, koja opcijski sadrži metilparaben i/ili propilparaben i/ili 0,9%-tni benzilni alkohol; normalne slane otopine ili fiziološke slane otopine, npr. 0,9%-tne otopine natrijevog klorida; 0,45%-tne ili 0,225%-tne otopine natrijevog klorida; te Ringerove otopine i/ili Ringerove laktatne otopine; pri čemu spomenuti sastav ima pH vrijednost poželjno od 5 do 8, još bolje od 6,0 do 7,5.
9. Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je to stabilna formulacija.
10. Farmaceutski sastav prema zahtjevu 8 ili formulacija prema zahtjevu 9,
naznačen(a) time, da pokazuje smanjeni broj sub-vidljivih čestica, dok spomenuta formulacija ima poželjno manje od 500, još bolje manje od 300 sub-vidljivih čestica po ampuli, pri čemu čestice imaju veličinu veću od 10 μm, a količinski broj čestica se određuje prema USP 27, <788> Ispitivanje broja čestica putem laganog zatamnjenja za kruti materijal od čestica u injekcijama.
11. Uporaba sastava prema bilo kojem od prethodnih zahtjeva, naznačena time, da je za proizvodnju lijeka, poželjno intravenoznog lijeka, za prevenciju i/ili liječenje gljivičnih infekcija ili stanja uzrokovanih s Candida sp. i/ili Aspergillus sp. i/ili s Pneumocystic jiroveci kod sisavca, posebno kod čovjeka.
12. Postupak za proizvodnju farmaceutskog sastava koji sadrži farmaceutski prihvatljivu sol kaspofungina, naznačen time, da taj postupak obuhvaća sljedeće korake:
1) otapanje punila za povećanje mase ili kombinacije takvih punila u vodi,
2) dodavanje kaspofungin diacetata ili kaspofungin dipropionata u otopinu dobivenu u koraku 1) te njezino otapanje,
3) filtriranje otopine dobivene u koraku 2),
4) zamrzavanje otopine dobivene u koraku 3), i
5) liofiliziranje zamrznute otopine;
pri čemu se ne dodaje nikakva dodatna količina sredstva za promjenu pH vrijednosti prilikom tvorbe sastava.
13. Sastav, naznačen time, da se dobiva postupkom prema zahtjevu 12.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117886 | 2006-07-26 | ||
| EP07109723 | 2007-06-06 | ||
| EP07819912.2A EP2049142B2 (en) | 2006-07-26 | 2007-07-24 | Caspofungin formulations |
| PCT/EP2007/057623 WO2008012310A1 (en) | 2006-07-26 | 2007-07-24 | Caspofungin formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20130109T1 HRP20130109T1 (en) | 2013-03-31 |
| HRP20130109T4 true HRP20130109T4 (hr) | 2016-05-20 |
Family
ID=38691922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130109TT HRP20130109T4 (hr) | 2006-07-26 | 2013-02-07 | Formulacije kaspofungina |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8232245B2 (hr) |
| EP (2) | EP2049142B2 (hr) |
| JP (1) | JP5373606B2 (hr) |
| KR (1) | KR101536781B1 (hr) |
| BR (1) | BRPI0715113A2 (hr) |
| CA (1) | CA2657817C (hr) |
| ES (1) | ES2401299T5 (hr) |
| HR (1) | HRP20130109T4 (hr) |
| PL (1) | PL2049142T5 (hr) |
| SI (1) | SI2049142T2 (hr) |
| WO (1) | WO2008012310A1 (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2692053A1 (en) * | 2007-06-26 | 2008-12-31 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
| WO2010005721A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| EP2183271A1 (en) * | 2008-06-25 | 2010-05-12 | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Caspofungin free of caspofungin impurity a |
| EP2240507A2 (en) * | 2008-06-25 | 2010-10-20 | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Processes for preparing high purity aza cyclohexapeptides |
| WO2010068866A2 (en) * | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| ES2776126T3 (es) * | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| WO2010108637A1 (en) * | 2009-03-27 | 2010-09-30 | Axellia Pharmaceuticals Aps | Crystalline compound |
| US8835382B2 (en) | 2009-11-23 | 2014-09-16 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
| JP5891175B2 (ja) | 2009-12-11 | 2016-03-22 | バインド セラピューティックス インコーポレイテッド | 治療用粒子の凍結乾燥に対する安定製剤 |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| CN102232932B (zh) * | 2010-04-27 | 2013-06-05 | 重庆莱美药业股份有限公司 | 果胶-阿霉素轭合物的冻干制剂及制备方法 |
| HUE030464T2 (en) * | 2010-09-20 | 2017-05-29 | Xellia Pharmaceuticals Aps | Caspofungin preparation |
| CN103180336B (zh) * | 2010-09-28 | 2016-06-15 | 中化帝斯曼制药有限公司荷兰公司 | 用于分离环六肽的方法 |
| CN102746384B (zh) * | 2011-04-22 | 2016-01-20 | 上海天伟生物制药有限公司 | 一种高纯度的卡泊芬净或其盐及其制备方法和用途 |
| CN104812381B (zh) | 2012-09-17 | 2018-01-26 | 辉瑞大药厂 | 用于制备治疗性纳米颗粒的方法 |
| PT2922530T (pt) * | 2012-11-20 | 2016-12-22 | Fresenius Kabi Usa Llc | Formulações de acetato de caspofungina |
| US20140256638A1 (en) * | 2013-02-14 | 2014-09-11 | The Regents Of The University Of California | Peptoid neutralizing agents |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| EP3054924B1 (en) | 2013-10-07 | 2020-11-25 | Galenicum Health S.L.U. | Stable pharmaceutical formulations of caspofungin |
| ME03435B (me) | 2014-03-14 | 2020-01-20 | Pfizer | Terapijske nanočestice koje sadrže terapijsko sredstvo,te postupci njihove proizvodnje i upotrebe |
| WO2017034961A1 (en) | 2015-08-21 | 2017-03-02 | Trilogy Therapeutics, Inc. | Methods of treating lung infection with caspofungin |
| KR101875512B1 (ko) | 2017-05-25 | 2018-07-06 | 이병돈 | 손잡이 각도가 조절되는 웨이트 트레이닝기구 |
| WO2019157453A1 (en) | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
| EP4051285A4 (en) * | 2019-10-28 | 2023-12-06 | Brillian Pharma Inc. | PHARMACEUTICAL UNIT DOSE SYSTEMS FOR ORAL DRY SOLUTION AND SUSPENSION |
| CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
| EP4364566A1 (en) * | 2022-11-04 | 2024-05-08 | B. Braun Melsungen AG | Anti-fungal composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5552521A (en) | 1995-02-10 | 1996-09-03 | Merck & Co., Inc. | Process for preparing certain aza cyclohexapeptides |
| AR006598A1 (es) | 1996-04-19 | 1999-09-08 | Merck Sharp & Dohme | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" |
| US5952300A (en) * | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| HRP970318B1 (en) | 1996-06-14 | 2002-06-30 | Merck & Co Inc | A process for preparing certain aza cyclohexapeptides |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| US6900184B2 (en) * | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
| KR101200227B1 (ko) † | 2005-05-04 | 2012-11-13 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 |
| EP1785432A1 (en) | 2005-11-15 | 2007-05-16 | Sandoz AG | Process and intermediates for the synthesis of caspofungin. |
-
2007
- 2007-07-24 SI SI200731128T patent/SI2049142T2/sl unknown
- 2007-07-24 JP JP2009521249A patent/JP5373606B2/ja not_active Expired - Fee Related
- 2007-07-24 US US12/374,489 patent/US8232245B2/en not_active Expired - Fee Related
- 2007-07-24 CA CA2657817A patent/CA2657817C/en not_active Expired - Fee Related
- 2007-07-24 KR KR1020097003863A patent/KR101536781B1/ko not_active IP Right Cessation
- 2007-07-24 WO PCT/EP2007/057623 patent/WO2008012310A1/en active Application Filing
- 2007-07-24 EP EP07819912.2A patent/EP2049142B2/en active Active
- 2007-07-24 BR BRPI0715113-6A patent/BRPI0715113A2/pt not_active IP Right Cessation
- 2007-07-24 ES ES07819912.2T patent/ES2401299T5/es active Active
- 2007-07-24 PL PL07819912.2T patent/PL2049142T5/pl unknown
- 2007-07-24 EP EP11162357A patent/EP2340846A1/en not_active Withdrawn
-
2012
- 2012-06-25 US US13/531,732 patent/US20130028940A1/en not_active Abandoned
-
2013
- 2013-02-07 HR HRP20130109TT patent/HRP20130109T4/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2401299T5 (es) | 2016-04-06 |
| WO2008012310A1 (en) | 2008-01-31 |
| CA2657817A1 (en) | 2008-01-31 |
| SI2049142T1 (sl) | 2013-02-28 |
| CA2657817C (en) | 2016-05-31 |
| US8232245B2 (en) | 2012-07-31 |
| EP2049142A1 (en) | 2009-04-22 |
| EP2340846A1 (en) | 2011-07-06 |
| ES2401299T3 (es) | 2013-04-18 |
| US20130028940A1 (en) | 2013-01-31 |
| HRP20130109T1 (en) | 2013-03-31 |
| KR101536781B1 (ko) | 2015-07-14 |
| JP5373606B2 (ja) | 2013-12-18 |
| KR20090046865A (ko) | 2009-05-11 |
| BRPI0715113A2 (pt) | 2013-06-04 |
| EP2049142B1 (en) | 2012-12-12 |
| PL2049142T3 (pl) | 2013-06-28 |
| SI2049142T2 (sl) | 2016-04-29 |
| EP2049142B2 (en) | 2016-01-20 |
| US20090170753A1 (en) | 2009-07-02 |
| JP2009544662A (ja) | 2009-12-17 |
| PL2049142T5 (pl) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130109T4 (hr) | Formulacije kaspofungina | |
| ES2227301T3 (es) | Composicion farmaceutica inyectable para la administracion sistematica de principios farmacologicamente activos que contienen trigliceridos de cadena media. | |
| ES2532595T3 (es) | Composición farmacéutica que contiene una nanopartícula de estatina encapsulada | |
| ES2226168T3 (es) | Una composicion farmaceutica que tiene dos capas de recubrimiento. | |
| AU2017345720B2 (en) | Terlipressin compositions and their methods of use | |
| JP2009506978A5 (hr) | ||
| JP2005528430A5 (hr) | ||
| ES2235834T3 (es) | Matriz directamente comprimible para la liberacion controlada de dosis diarias unicas de claritromicina. | |
| CA3146475A1 (en) | Pharmaceutical formulation | |
| JP5497336B2 (ja) | 薬物を保持した脂肪粒子を含む非水系組成物およびその製造方法 | |
| WO2013024373A1 (en) | Pharmaceutical composition comprising cefuroxime | |
| JP5000017B2 (ja) | 微粒子コーティング製剤 | |
| EP2538923A2 (en) | Taste-masked powder for suspension compositions of methylprednisolone | |
| CA2785360C (en) | Treating critically ill patients with intravenous ibuprofen | |
| KR20190110457A (ko) | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 | |
| WO2017177160A1 (en) | Formulation for use in a method of treatment of pain | |
| CN1447688A (zh) | 使用苯甲酰苯乙酸治疗与血管生成相关疾病的方法 | |
| KR102365008B1 (ko) | 디쿠아포솔을 포함하는 점안 조성물 | |
| JP2011046666A (ja) | 医薬組成物 | |
| JP5191121B2 (ja) | 溶解性を改善したジフェンヒドラミン含有医薬組成物 | |
| US20190321318A1 (en) | Droxidopa compositions and methods | |
| CN1857220B (zh) | 一种抗结核病药物缓释剂 | |
| CN101254169A (zh) | 含抗结核病药物的缓释剂 | |
| KR20070061578A (ko) | 눈물 및 침 건조증 치료용 의약 조성물 | |
| JP2009018993A (ja) | 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤 |